Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab

J Dermatolog Treat. 2023 Dec;34(1):2242540. doi: 10.1080/09546634.2023.2242540.

Authors

Yan Yang¹, Jiaoquan Chen¹, Nanji Yu¹, Yanan Ke¹, Aili Gao¹, Siying Xiong¹, Xiaolan Zhao¹, Yumei Liu¹, Huilan Zhu¹

Affiliation

¹ Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, Guangdong, China.

PMID: 37526019
DOI: 10.1080/09546634.2023.2242540

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
upadacitinib
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal